IntelliCyt Corporation Announces First Instrument for 1536 Screening in Suspension for Drug Discovery Market

Share Article

New iQue Screener HD ideal for large-scale phenotypic screening.

IntelliCyt Corporation, a provider of assay screening solutions for phenotypic drug discovery, antibody discovery and in vitro toxicity testing, announced the new iQue™ Screener HD, the first commercially available instrument for screening in suspension using the 1536 well microplate format. It is the latest addition to IntelliCyt’s platform of instrumentation, application-specific reagents, integrated multi-user analysis and informatics tools. The new iQue Screener HD was featured at the Society for Laboratory Automation and Screening (SLAS2014) held in San Diego this week.

“Reception to iQue Screener since our introduction last January has been very positive. It has enabled our customers to drastically reduce time and cost for their cell and bead-based screening assays,” commented Terry Dunlay, CEO at IntelliCyt. “iQue Screener HD extends these savings by reducing the required assay volume even more. By supporting the 1536 well format, we are well positioned to serve the most innovative and highest throughput screening laboratories. Early response at this year’s SLAS conference was very favorable.”

About IntelliCyt Corporation
IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. For more information, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

R. Terry Dunlay, President and CEO
Like >
Follow us on
Visit website